The legislation would allow drugmakers to share economic information with payers beyond what is included on the FDA-approved label.
The FDA's advertising division said images and copy for the BPH drug Rapaflo are misleading.
Researchers say Twitter could provide critical insight into health needs for hard-to-reach groups.
CVS will buy institutional pharmacy Omnicare in a $12.7-billion deal; ProPublica says the FDA and GlaxoSmithKline failed to protect patients from misusing Advair; Regeneron and Sanofi expect to file RA drug sarilumab with the FDA in the fourth quarter of this year
Even the industry's sunniest personalities don't deny that pharma has an image problem among outside constituencies, with an unfortunately high percentage of observers believing the biz is first and foremost about profits. Sachin Jain dives deep on this and other perceptions—accurate and otherwise—about the industry and its marketing machinery
The West Coast independent agency redefined its leadership team with the appointments of founding principal Steven Gold as CEO and Jeff Nemy as CFO.
The FDA's bad-ad group said the banner they saw at a professional conference was misleading.
FDA official says DTC risk claims are a waste of time; one analyst believes Afrezza could turn around sluggish sales; J&J inks billion-dollar deal to commercialize HCV drugs
The new Centron includes renamed medical education, public relations and market access divisions.
McNeil Consumer Healthcare president Denice Torres was named woman of the year by the Healthcare Businesswomen's Association.
Parties in the effort say the novelty of wearing an Apple Watch, along with a newly developed app, may help clinicians refine treatment plans and patient support.
Perrigo says a Mylan deal is possible; new guidelines may reduce cancer screenings; Takeda petitions dictionaries to add a new definition for depression
Experts say Afrezza's tepid launch may have more to do with value proposition than product positioning.
Endo agrees to buy Par Pharmaceuticals for $8 billion; AstraZeneca deepens commitment to biologics; FDA cautions that certain diabetes drugs could lead to serious condition
Long-time practice lead Gil Bashe is tasked with unifying and building the health function at global firm Finn Partners.
The 2015 healthcare agency questionnaire, for firms hoping to be featured in the Top 100 Agencies issue, is live. Click here to be considered.